The Current Ratio as of December 2024 (TTM) for Syndax Pharmaceuticals, Inc. (SNDX) is 6.99

According to Syndax Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.99. This represents a change of -23.27% compared to the average of 9.11 of the last 4 quarters.

Syndax Pharmaceuticals, Inc. (SNDX) Historical Current Ratio (quarterly & annually)

How has SNDX Current Ratio performed in the past?

The mean historical Current Ratio of Syndax Pharmaceuticals, Inc. over the last ten years is 11.09. The current 6.99 Current Ratio has changed 6.20% with respect to the historical average. Over the past ten years (40 quarters), SNDX's Current Ratio was at its highest in in the December 2021 quarter at 21.68. The Current Ratio was at its lowest in in the March 2015 quarter at 0.

Syndax Pharmaceuticals, Inc. (SNDX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Syndax Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Syndax Pharmaceuticals, Inc. (SNDX) Average Current Ratio

How has SNDX Current Ratio performed in the past?

The current Current Ratio of Syndax Pharmaceuticals, Inc. (SNDX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Syndax Pharmaceuticals, Inc. (SNDX) Current Ratio vs. Peers

How is SNDX’s Current Ratio compared to its peers?

Syndax Pharmaceuticals, Inc.’s Current Ratio is greater than Cogent Biosciences, Inc. (6.44), less than Cullinan Oncology, Inc. (24.46), greater than KalVista Pharmaceuticals, Inc. (6.87), greater than Mersana Therapeutics, Inc. (2.35), less than Pliant Therapeutics, Inc. (10.26), less than Revolution Medicines, Inc. (14.24), less than Viridian Therapeutics, Inc. (18.55), less than Inozyme Pharma, Inc. (7.68), less than Aerovate Therapeutics, Inc. (8.78), less than Keros Therapeutics, Inc. (19.03), less than Mineralys Therapeutics, Inc. (8.55), less than Replimune Group, Inc. (10.11), less than Vaxcyte, Inc. (17.88), less than Larimar Therapeutics, Inc. (13.10), less than Merus N.V. (8.32), greater than Sutro Biopharma, Inc. (3.09), less than Cytokinetics, Incorporated (9.28), less than DICE Therapeutics, Inc. (38.14), less than Edgewise Therapeutics, Inc. (26.35), less than Karuna Therapeutics, Inc. (19.31), less than Dyne Therapeutics, Inc. (17.02),

Build a custom stock screener for Syndax Pharmaceuticals, Inc. (SNDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syndax Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Syndax Pharmaceuticals, Inc. (SNDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Syndax Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.